lovastatin has been researched along with Fibrosarcoma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fritz, G; Huelsenbeck, J; Nilsson, S | 1 |
| Byrom, M; Cha, HJ; Ellington, AD; Marcotte, EM; Mead, PE; Wallingford, JB | 1 |
| Ciocca, DR; Cuello Carrión, FD; Gervasoni, SI; Matar, P; Rozados, VR; Scharovsky, OG | 1 |
| Hamilton, AD; Qian, Y; Sebti, SM; Sun, J; Vogt, A | 1 |
| Afrakhte, M; Karlsson, C; Paulsson, Y; Westermark, B | 1 |
| Matar, P; Roggero, EA; Rozados, VR; Scharovsky, OG | 1 |
6 other study(ies) available for lovastatin and Fibrosarcoma
| Article | Year |
|---|---|
Mevalonate pathway inhibitors affect anticancer drug-induced cell death and DNA damage response of human sarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Cycle; Cell Proliferation; Cisplatin; Diphosphonates; DNA Damage; Doxorubicin; Fibrosarcoma; Humans; Lovastatin; Metformin; Mevalonic Acid; Osteosarcoma; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Evolutionarily repurposed networks reveal the well-known antifungal drug thiabendazole to be a novel vascular disrupting agent.
Topics: Angiogenesis Inhibitors; Animals; Antifungal Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Fibrosarcoma; Gene Knockdown Techniques; Gene Regulatory Networks; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Lovastatin; Mice; Neovascularization, Physiologic; rab GTP-Binding Proteins; Thiabendazole; Time-Lapse Imaging; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays; Xenopus laevis | 2012 |
Hsp25 and Hsp70 in rodent tumors treated with doxorubicin and lovastatin.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Doxorubicin; Drug Resistance, Neoplasm; Endothelium, Vascular; Female; Fibrosarcoma; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Lovastatin; Lymphoma, B-Cell; Mammary Neoplasms, Animal; Mice; Mice, Inbred Strains; Molecular Chaperones; Neoplasm Proteins; Rats; Rats, Inbred Strains | 2003 |
The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner.
Topics: Alkyl and Aryl Transferases; Benzamides; Breast Neoplasms; Cell Cycle; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Inhibitors; Female; Fibrosarcoma; G1 Phase; Head and Neck Neoplasms; Humans; Lovastatin; Methionine; Oligopeptides; Pancreatic Neoplasms; Protein Prenylation; Resting Phase, Cell Cycle; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 1997 |
Elevated level of gas3 gene expression is correlated with G0 growth arrest in human fibroblasts.
Topics: Aged; Antineoplastic Agents; Blotting, Northern; Cellular Senescence; Fibroblasts; Fibrosarcoma; Gene Expression Regulation, Neoplastic; Humans; Infant; Kinetics; Lovastatin; Myelin Proteins; Resting Phase, Cell Cycle; RNA, Messenger; Skin; Tumor Cells, Cultured | 1999 |
Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma.
Topics: Animals; Antineoplastic Agents; Cell Division; Cholesterol; Fibrosarcoma; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Neoplasm Metastasis; Rats; Rats, Inbred Strains; Sarcoma, Experimental | 1998 |